WASHINGTON, D.C., April 14, 2021 -- Coherus BioSciences, Inc.’s (“Coherus”, Nasdaq: CHRS), CEO Denny Lanfear today issued a public statement of support regarding the passage of the Advancing Education on Biosimilars Act of 2021 (S.164).
“Today marks yet another achievement supporting the growing demand of biosimilars. I am pleased to see the government stepping up to further promote biosimilars, and I commend this bipartisan initiative led by U.S. Senators Maggie Hassan and Bill Cassidy and leaders in the House of Representatives. This bill will now be sent to President Biden and we encourage him to sign this into law. With the passage of the Advancing Education on Biosimilars Act of 2021 (S.164), it is clear Washington wants to lower drug prices by educating patients and providers about lower cost alternatives. However, more work needs to be done in promoting biosimilars, such as consideration of the Bolstering Innovative Options to Save Immediately on Medicines Act (BIOSIM Act). Coherus looks forward to continuing our partnerships with policymakers and regulators to advance biosimilar policies that help taxpayers, Medicare patients, and our provider partners.”